Effects of Prednisolone, l-Asparaginase, Gemfibrozil, and Combinations of These Elements on Mice Lipid Profile, Liver, and Pancreas

dc.contributor.authorKose, Dogan
dc.contributor.authorTarakci, Nuriye
dc.contributor.authorCelik, Zeliha Esin
dc.contributor.authorVatansev, Husamettin
dc.contributor.authorCimbek, Emine Ayca
dc.contributor.authorUgras, Serdar
dc.contributor.authorSen, Yasar
dc.date.accessioned2024-02-23T14:21:16Z
dc.date.available2024-02-23T14:21:16Z
dc.date.issued2016
dc.departmentNEÜen_US
dc.description.abstractThe aim of this study is to determine the effects of l-asparaginase (l-ASP), corticosteroids (CSs), and antilipidemics, separately and in combination, on the lipid profiles and the liver and pancreas histology in mice. This study included 8 groups of 7 mice each. Before any drug administration, serum samples were taken from all of the mice. Then, normal saline was applied to the control group, and a medication or combination of medications was applied to the other groups. Levels of triglycerides, cholesterol (COL), and high-density lipoprotein (HDL) and low-density lipoprotein (LDL) were determined, and the livers and pancreases were evaluated histologically at the end of the study. Triglycerides increased significantly in the CS-only and the l-ASP-only groups, COL increased significantly in the CS-only group, and HDL increased significantly in the CS-only and the antilipidemic-only groups. LDL was significantly lower in the CS-only and the l-ASP-only groups. CSs and l-ASP were significantly effective in liver necrosis, l-ASP was significantly effective in liver balloon degeneration, and CS were significantly effective in pancreas vacuolization. Triglyceride measurement is recommended before/during CS and/or l-ASP treatment. Starting with an antilipidemic agent can be considered to avoid possible complications in patients with significantly high rates. Indicators of a possible liver or pancreas injury should also be considered.en_US
dc.description.sponsorshipSelcuk Universityen_US
dc.description.sponsorshipSupported by Selcuk University.en_US
dc.identifier.doi10.1097/MPH.0000000000000484
dc.identifier.endpageE49en_US
dc.identifier.issn1077-4114
dc.identifier.issn1536-3678
dc.identifier.issue1en_US
dc.identifier.pmid26599986en_US
dc.identifier.scopus2-s2.0-84952863927en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpageE42en_US
dc.identifier.urihttps://doi.org/10.1097/MPH.0000000000000484
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13525
dc.identifier.volume38en_US
dc.identifier.wosWOS:000372838700012en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofJournal Of Pediatric Hematology Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPrednisoloneen_US
dc.subjectLipiden_US
dc.subjectAsparaginaseen_US
dc.subjectGemfibrozilen_US
dc.titleEffects of Prednisolone, l-Asparaginase, Gemfibrozil, and Combinations of These Elements on Mice Lipid Profile, Liver, and Pancreasen_US
dc.typeArticleen_US

Dosyalar